- Home
- FIEE vs CRVO Comparison
FIEE vs CRVO Comparison
Compare FIEE & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIEE | CRVO |
|---|---|---|
| Founded | 1977 | 2001 |
| Country | Hong Kong | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 37.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | FIEE | CRVO |
|---|---|---|
| Price | $7.60 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 11.3K | ★ 30.1K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $3.51 |
| 52 Week High | $7.95 | $13.13 |
Technical Indicators
Market Signals| Indicator | FIEE | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.11 | 46.22 |
| Support Level | $2.45 | $3.55 |
| Resistance Level | $7.88 | $4.41 |
| Average True Range (ATR) | 0.20 | 0.29 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 76.74 | 39.83 |
Price Performance
Historical ComparisonAbout FIEE FiEE Inc
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.